Thanks for the primer Koo ... really looking forward to the curtain being pulled back on BoM eGFR data, good or bad, for clarity. If BoM does NOT show significant improvement with BoM preliminary data for eGFR (and AP's?), then what exactly is the biological ralationship that makes low eGFR/GFR patients so much better for cardio improvments? Just overall sickly patients, but "why"?! Those types of impacts and relationships need to be better understood for widespread acceptance. Of course, ideally, we will hear of direct biological marker benefits which make apabetalone a potential cardio and renal indication, in diabetic patients. Sure hope the conference occurs late March, but I suppose the information will come out soon either way, in papers and publications, and/or virtual showcasing. 

Let's goooooo :)